MX2022006910A - Tratamiento para la leucemia mieloide aguda o para el síndrome mielodisplásico. - Google Patents
Tratamiento para la leucemia mieloide aguda o para el síndrome mielodisplásico.Info
- Publication number
- MX2022006910A MX2022006910A MX2022006910A MX2022006910A MX2022006910A MX 2022006910 A MX2022006910 A MX 2022006910A MX 2022006910 A MX2022006910 A MX 2022006910A MX 2022006910 A MX2022006910 A MX 2022006910A MX 2022006910 A MX2022006910 A MX 2022006910A
- Authority
- MX
- Mexico
- Prior art keywords
- myeloid leukemia
- myelodysplastic syndrome
- acute myeloid
- treatment
- lymphoma
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962944876P | 2019-12-06 | 2019-12-06 | |
| PCT/CA2020/051668 WO2021108918A1 (en) | 2019-12-06 | 2020-12-04 | Treatment for acute myeloid leukemia or myelodysplastic syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022006910A true MX2022006910A (es) | 2022-11-09 |
Family
ID=76221282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022006910A MX2022006910A (es) | 2019-12-06 | 2020-12-04 | Tratamiento para la leucemia mieloide aguda o para el síndrome mielodisplásico. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12533357B2 (enExample) |
| EP (1) | EP4069246A4 (enExample) |
| JP (1) | JP2023505301A (enExample) |
| KR (1) | KR20220124177A (enExample) |
| CN (1) | CN115397429A (enExample) |
| AU (1) | AU2020396807B2 (enExample) |
| BR (1) | BR112022011052A2 (enExample) |
| CA (1) | CA3163796A1 (enExample) |
| IL (1) | IL293623A (enExample) |
| MX (1) | MX2022006910A (enExample) |
| TW (1) | TWI880995B (enExample) |
| WO (1) | WO2021108918A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7337539B2 (ja) * | 2018-06-21 | 2023-09-04 | メディヴィル・アクチエボラーグ | 白血病療法のための塩基修飾シチジンヌクレオチド |
| TWI926033B (zh) | 2021-05-11 | 2026-05-21 | 美商歐瑞克製藥公司 | 類ｐｏｌｏ激酶４抑制劑 |
| TW202333712A (zh) * | 2021-12-22 | 2023-09-01 | 加拿大健康網路大學 | 於急性骨髓性白血病或淋巴瘤之治療 |
| CN117180295A (zh) * | 2023-09-13 | 2023-12-08 | 华东医院 | 一种用于治疗tp53突变髓系肿瘤的药物组合物及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010115279A1 (en) | 2009-04-06 | 2010-10-14 | University Health Network | Kinase inhibitors and method of treating cancer with same |
| TWI516262B (zh) | 2010-04-06 | 2016-01-11 | 健康網路大學 | 激酶抑制劑及以其治療癌症的方法 |
| CA2803446C (en) * | 2010-07-02 | 2019-06-04 | University Health Network | Use of plk4 antagonists for treating pten mutant diseases |
| WO2012048411A1 (en) * | 2010-10-13 | 2012-04-19 | University Health Network | Plk-4 inhibitors and method of treating cancer with same |
| EP3052102B1 (en) | 2013-10-04 | 2019-12-04 | Aptose Biosciences Inc. | Compositions for treating cancers |
| TR201902875T4 (tr) * | 2013-10-18 | 2019-03-21 | Univ Health Network | Plk-4 inhibitörünün tuz ve kristal formları. |
| WO2015116696A1 (en) | 2014-01-28 | 2015-08-06 | Massachusetts Institute Of Technology | Combination therapies and methods of use thereof for treating cancer |
| KR20190129889A (ko) | 2017-03-31 | 2019-11-20 | 노파르티스 아게 | 혈액 종양에서 HDM2-p53 상호작용 억제제의 용량 및 요법 |
| JP7343483B2 (ja) * | 2017-09-08 | 2023-09-12 | ユニバーシティー ヘルス ネットワーク | Ｐｏｌｏ様キナーゼ４の阻害のための併用療法 |
| US11612604B2 (en) * | 2017-12-06 | 2023-03-28 | Ludwig Institute For Cancer Research Ltd | Methods of treating cancer with PLK4 inhibitors |
| EP3959209A4 (en) | 2019-04-24 | 2022-12-28 | University Health Network | S4 CRYSTALLINE FORM OF A PLK4 INHIBITOR (1R,2S)-(E)-2-(3-(4-((CIS-2,6-DIMETHYLMORPHOLINO)METHYL)STYRYL)-1H-IMIDAZOL-6-YL )-5'-METHOXYSPIRO[CYCLOPROPANE-L,3'-INDOLIN]-2'-ONE FUMARATE |
-
2020
- 2020-12-04 KR KR1020227023046A patent/KR20220124177A/ko active Pending
- 2020-12-04 CA CA3163796A patent/CA3163796A1/en active Pending
- 2020-12-04 JP JP2022534233A patent/JP2023505301A/ja active Pending
- 2020-12-04 AU AU2020396807A patent/AU2020396807B2/en active Active
- 2020-12-04 US US17/782,632 patent/US12533357B2/en active Active
- 2020-12-04 WO PCT/CA2020/051668 patent/WO2021108918A1/en not_active Ceased
- 2020-12-04 IL IL293623A patent/IL293623A/en unknown
- 2020-12-04 MX MX2022006910A patent/MX2022006910A/es unknown
- 2020-12-04 BR BR112022011052A patent/BR112022011052A2/pt unknown
- 2020-12-04 TW TW109142965A patent/TWI880995B/zh active
- 2020-12-04 CN CN202080095784.4A patent/CN115397429A/zh active Pending
- 2020-12-04 EP EP20895810.8A patent/EP4069246A4/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020396807A1 (en) | 2022-07-21 |
| JP2023505301A (ja) | 2023-02-08 |
| US12533357B2 (en) | 2026-01-27 |
| EP4069246A1 (en) | 2022-10-12 |
| US20230010772A1 (en) | 2023-01-12 |
| CA3163796A1 (en) | 2021-06-10 |
| IL293623A (en) | 2022-08-01 |
| CN115397429A (zh) | 2022-11-25 |
| BR112022011052A2 (pt) | 2022-08-16 |
| EP4069246A4 (en) | 2023-12-06 |
| WO2021108918A1 (en) | 2021-06-10 |
| TW202134237A (zh) | 2021-09-16 |
| AU2020396807B2 (en) | 2026-07-16 |
| TWI880995B (zh) | 2025-04-21 |
| KR20220124177A (ko) | 2022-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021000737A1 (es) | Fabricación de compuestos y composiciones para inhibir la actividad de shp2 | |
| MX2024003295A (es) | Compuesto agonista del receptor thrb y metodo de preparacion y uso del mismo. | |
| CO2021016504A2 (es) | Inhibidores de cdk | |
| MX2024002538A (es) | Uso de un inhibidor de la ezh2 en la preparacion de farmacos para el tratamiento del linfoma de linfocitos t. | |
| AR123996A2 (es) | Compuestos tricíclicos novedosos como agentes antineoplásicos | |
| MX388748B (es) | Métodos de tratamiento mediante el uso de un compuesto inhibidor de jak. | |
| ECSP19030134A (es) | Compuesto de piridina | |
| MX2012001654A (es) | Metodos para usar moduladores de c-met. | |
| BR112022011052A2 (pt) | Tratamento para leucemia mieloide aguda ou síndrome mielodisplásica | |
| EA201690608A1 (ru) | Способы лечения раковых заболеваний | |
| CR20120177A (es) | Nuevos compuestos de espiropiperidina y el uso farmacéutico del mismo para el tratamiento de diabetes | |
| CL2018002583A1 (es) | Derivado de morfolina | |
| PY21111338A (es) | COMPUESTOS Y COMPOSICIÓN PARA EL TRATAMIENTO DE CONDICIONES ASOCIADAS CON cGAS | |
| MX2025002218A (es) | Metodos de tratamiento de tumores solidos que presentan alteraciones activadoras del gen fgfr3 | |
| MX2024003877A (es) | Procedimientos de preparacion de un compuesto macrociclico con actividad inhibidora de la ent1. | |
| CL2023003758A1 (es) | Pirimidinil-pirazoles sustituidos como inhibidores de cdk2 | |
| MX2017003780A (es) | Composicion farmaceutica para tratar colitis ulcerativa. | |
| CL2025001760A1 (es) | Compuesto quimérico protac, método de preparación del mismo y uso del mismo | |
| MX2018014080A (es) | Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia. | |
| CL2017002960A1 (es) | Compuesto para la profilaxis o el tratamiento de daño al órgano | |
| MX384724B (es) | Regímenes de dosificación de melflufen para cáncer. | |
| AR105821A1 (es) | COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T | |
| CO2022008127A2 (es) | Procesos e intermediario para la preparación de oxetan-2-ilmetanamina | |
| CO2019007836A2 (es) | Derivados de pirrolotriazina como inhibidor de cinasas | |
| CO2018005064A2 (es) | Bloqueador del canal de sodio |